| Budget Amount *help |
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 1996: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 1995: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Research Abstract |
We developed a novel polyclonal antibody against advanced glycation end products (AGEs) in 1995. By using the antibody, we studied the immunohistochemical analysis in the brain tissue of Alzheimer's disease, and its related disorders. Also, we examined the therapeutic effects for diabetic nephropathy by a newly developed AGE inhibitor.
In summary
1) By using AGE antibody, we developed an ELISA for the measurement of AGE,and immunohistochemical technique for the detection of AGE accumulation in vivo.
2) We demonstrated that AGEs had oxic effects.
3) AGEs accumulated the brain tissue in Alzheimer's disease, Pick's disease, progressive supranuclear palsy, and Parkinsonism-dementia complex of Guam.
4) In Alzheimer's disease, AGEs accumulation occurred in the core of senile plaques.
5) A novel AGE inhibitor prevented the progression of diabetic nephropathy.
|
